RESUMEN
Background: Non-Hodgkin's lymphoma (NHL) with cardiac infiltration has a poor prognosis. The median OS of patients failing to respond to chemotherapy has been reported to be 1 month vs. 18 months in patients responding to chemotherapy. Case presentation: Herein, we reported a case of a 57-year-old male confirmed with diffuse large B-cell lymphoma who received radiation therapy of 150-cGy daily, administered in 30 fractions to the volume of cardiac infiltration, resulting in complete relief. Chemotherapy had no curative effect. The patient was subsequently enrolled in a clinical trial and received oral administration of zanubrutinib 80mg twice daily, after which he achieved complete remission. The progression-free survival was from diagnosis (January 7, 2020) to the follow-up (September 20, 2022), amounting to 32 months. Conclusion: Proper irradiation dose and timing of treatment can relieve NHL symptoms.
RESUMEN
This study aimed to investigate the risk factors influencing the prognosis of patients receiving conventional fractionation radiotherapy. A retrospective analysis of clinical data from 100 patients with nasopharyngeal carcinoma receiving radiotherapy was conducted. The Chi-square test was used to screen the relevant factors and Cox multiple-factor analysis was used to investigate the risk factors influencing the survival of patients. One-factor analysis results revealed that tumor stage, tumor diameter, prescription dose completion and radiotherapy regularity are related to the prognosis of nasopharyngeal carcinoma and multiple-factor analysis results revealed that tumor stage, radiotherapy dose and radiotherapy regularity are independent risk factors influencing prognosis. The prognosis of patients with nasopharyngeal carcinoma receiving radiotherapy is related to tumor progression and an adequate dose of regular radiotherapy improves the prognosis of patients.
RESUMEN
BACKGROUND & OBJECTIVE: Radiotherapy is an important treatment for nasopharyngeal carcinoma (NPC). Timing of radiotherapy has attracted more attention nowadays. This study was to assess the efficacy of accelerated fractionation (six fractions per week) versus conventional fractionation (five fractions per week) for NPC, thus to improve treatment efficacy without increasing complications. METHODS: Three hundred and thirty-nine NPC patients treated with radiotherapy were retrospectively analyzed, including 181 patients in the accelerated fractionation group and 158 patients in the conventional fraction group. All patients were radiated using a 6MV X-ray beam, 2 Gy per fraction, once a day. A total dose (TD) of 64-72 Gy, divided into 32-36 fractions, were irradiated to the nasopharyngeal regionû a TD of 62-68 Gy, divided into 31-34 fractions, were irradiated to the cervical region. The TD of prophylaxsis was 50-52 Gy, divided into 25-26 fractions. All N3 patients received adjunct chemotherapy. RESULTS: The 1-, 3-and 5-year local control and survival rates of the accelerated fractionation group and the conventional fractionation group were (98.9% and 98.3%) vs. (98.1% and 96.8%), (95.5% and 91.2%) vs. (88.2% and 80.4%), (87.3% and 69.6%) vs. (76.6% and 51.3%), respectively. The 3-and 5-year local control and overall survival rates between the two groups were significantly different (P=0.079 and P=0.0011 vs. P=0.09 and P=0.0001). The incidence of acute reactions was higher in the accelerated fractionation group than in the conventional fractionation groupû but the incidence of delayed reactions between the two groups was not significantly different. The disease-free survival was significantly longer in the accelerated fractionation group than in the conventional fractionation group (P=0.002). CONCLUSION: Compared with conventional fractionation, accelerated fractionation significantly improves the 3-and 5-year local control and overall survival rates, as well as the disease-free rate for NPC patients without increasing delayed toxicity.
